Figure 1. VDZ does not affect CDC or ADCC. (A) PBMCs were incubated with increasing concentrations of VDZ, OKT3, or human IgG₁ in the presence of rabbit complement. Spontaneous lysis of the cells in the presence of 10 µg/mL of each antibody in the absence of complement is shown (n = 4). (B) CD20⁺ α₄β₇⁺ RPMI8866 cells were incubated with increasing concentrations of either VDZ, rituximab (anti-CD20), or ACT-1 (the murine precursor of VDZ) in the presence of PBMCs. Spontaneous lysis of the cells in the presence of 10 µg/mL of each antibody in the absence of either effectors (PBMCs) or targets (RPMI8866) is shown (n = 3). Results are representative of 3 experiments.